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M A J O R A R T I C L E
Effects of Primary Metronidazole and Clarithromycin
Resistance to Helicobacter pylori on Omeprazole,
Metronidazole, and Clarithromycin Triple-Therapy
Regimen in a Region with High Rates
of Metronidazole Resistance
Wai Man Wong,1 Qing Gu,1,2 Wei Hong Wang,1,2 Fiona Man-Yee Fung,1 Douglas E. Berg,3 Kam Chuen Lai,1
Harry Hua-Xiang Xia,1 Wayne H. C. Hu,1 Chi Kuen Chan,1 Annie On-On Chan,1 Man-Fung Yuen,1 Chee-Kin Hui,1
Shiu Kum Lam,1 and Benjamin Chun-Yu Wong1
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, and 2Department of Medicine, Beijing Medical University
First Teaching Hospital, Beijing, China; and 3Department of Molecular Microbiology, Washington University Medical School, St. Louis, Missouri
The aim of this study was to investigate the effect of metronidazole resistance (MtzR) and clarithromycin
resistance (ClaR) on the eradication rate for omeprazole, clarithromycin, and metronidazole triple-therapy
regimen and on the development of posttherapy drug resistance in a region of high rates of MtzR. One hundred
ninety-six Helicobacter pylori isolates were recovered from patients with duodenal ulcer, gastric ulcer, or
nonulcer dyspepsia during upper endoscopy. The prevalences of MtzR, ClaR, and dual resistance were 37.8%,
13.8%, and 8.7%, respectively. The intention-to-treat eradication rates for metronidazole-susceptible (87.2%
vs. 67.6%; ) and clarithromycin-susceptible (86.4% vs. 40.7%; ) strains were significantly higherPp .001 P ! .001
than the rates for resistant strains. Multiple logistic regression analysis implicated younger age (!40 years
old), MtzR, ClaR, and the diagnosis of nonulcer dyspepsia as independent factors that predicted treatment
failure. The rates of posttreatment MtzR, ClaR, and dual resistance were 88%, 88%, and 75%, respectively.
MtxR and ClaR significantly affected the success of eradication therapy. Posttreatment rates of resistance were
high and were related to the presence of pretreatment antibiotic resistance.
Helicobacter pylori plays an important role in the path-
ogenesis of peptic ulcer disease, gastric maltoma, and
adenocarcinoma of the stomach [1]. Effective antimi-
crobial therapy for H. pylori has proven to be effective
treatment for peptic ulcer disease [2–5]. At the Asia–
Pacific Consensus Conference on the Management of
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Helicobacter pylori Infection (Singapore), the regimens
recommended included the use of proton pump in-
hibitor (PPI)/ranitidine bismuth citrate at a standard
dose, plus 2 antibiotics (clarithromycin plus either
amoxicillin or metronidazole), each given twice per day
for 7 days [1]. However, metronidazole resistance to
H. pylori is common, especially in developing countries.
For example, the prevalence of H. pylori resistance to
metronidazole is 10%–45% in the United States and
Europe and 50%–90% in developing countries [6–13].
Several years ago, some of us reported that approxi-
mately one-half of the H. pylori strains in Hong Kong
were resistant to metronidazole, and the frequency of
metronidazole resistance was lower among persons with
duodenal ulcer than among asymptomatic control
subjects [12]. However, others have not observed
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such trends, which has raised questions concerning the gen-
erality or even reproducibility of the trends that we observed
[9, 11, 13]. We are drawn to the possibility that metronidazole-
resistant strains might be less virulent on average than me-
tronidazole-susceptible strains, especially because of recent
findings that most cases of clinically significant metronidazole
resistance result from loss-of-function mutations in 1 gene
(moderate resistance) or several genes (high resistance) that
encode a cellular nitroreductase, which converts metronidazole
from a harmless prodrug to bactericidal agent [14, 15]. It is
attractive to imagine that the potential metabolic changes, even
though obviously not lethal to H. pylori (given the high level
of metronidazole resistance), might decrease the vigor of its
growth and, thereby, its virulence [15]. Studies of the effect of
metronidazole resistance on the efficacy of antimicrobial treat-
ment for H. pylori infection have shown that the eradication
rate is ∼90% for susceptible strains but !75% for resistant
strains [16–18]. These studies were summarized by a meta-
analysis, which found that the effect of nitroimidazole resistance
on the efficacy of nitroimidazole-containing anti–H. pylori reg-
imens was determined by the treatment duration and the com-
ponents of the regimen [19].
Pretreatment clarithromycin resistance is one of the most
important factors for determining the efficacy of H. pylori erad-
ication therapy. It decreases the eradication rate by an average
of 55%, according to a meta-analysis [20]. Moreover, the failure
of a clarithromycin-based regimen may lead to the development
of secondary clarithromycin resistance. In a large, multina-
tional, multicenter, randomized clinical trial that assessed the
efficacy of PPI-based triple-therapy regimen for the treatment
of H. pylori infection [21], secondary resistance to clarithro-
mycin occurred in strains recovered from 12 (11.4%) of 105
patients after treatment failure with a clarithromycin-based reg-
imen [22]. Others have reported that the secondary clarith-
romycin-resistance rate after receipt of amoxicillin-clarithro-
mycin-omeprazole triple-therapy for 1 week was ∼23% [23].
In the present study, we have examined the impact of pre-
treatment metronidazole resistance and clarithromycin resis-
tance on the efficacy of omeprazole-clarithromycin-metroni-
dazole triple-therapy in a region with a high prevalence of
metronidazole resistance. The study aimed to find out (1)
whether the prevalence of metronidazole and clarithromycin
resistance correlates with clinical manifestation, (2) whether the
eradication rate depends on antibiotic resistance and/or other
risk factors, and (3) the prevalence of posttreatment antibiotic
resistance after failure of eradication.
METHODS
Patient population. Consecutive patients referred to the en-
doscopy unit of the Department of Medicine, Queen Mary
Hospital, University of Hong Kong (Hong Kong, China), for
the investigation of dyspepsia were considered for study re-
cruitment. Dyspepsia was defined as persistent or recurrent
upper abdominal pain or discomfort during the previous 3-
month period, in accordance with the Rome criteria for dys-
pepsia [24]. Informed written consent was obtained from all
patients who participated in the study. Duodenal ulcer and
gastric ulcer were determined endoscopically and defined as a
break in the mucosa of3 mm in diameter. Nonulcer dyspepsia
was defined as no active lesions found by endoscopy or any
lesions suggestive of a previous ulcer, such as an ulcer scar, a
deformity, or a mucosal irregularity, and no past history of
peptic ulcer diseases. Inclusion criteria included age of 18–80
years and demonstrated H. pylori infection. H. pylori infection
was determined by 2 positive results of a rapid urease test
(RUT), a histological test, and/or a 13C-urea breath test (13C-
UBT) and positive H. pylori culture results. Exclusion criteria
included presence of severe concomitant illness, active gastro-
intestinal bleeding, or histologically proven gastric cancer; re-
ceipt of aspirin, other nonsteroidal anti-inflammatory drugs
(NSAIDs), antibiotics, H2 receptor blockers, bismuth, or PPIs
in the preceding 4 weeks; and history of eradication of H. pylori
or previous gastric surgery. This study was approved by the
ethics committee of the University of Hong Kong.
Gastric biopsies and histological examination. During
upper endoscopy, 3 antral biopsy and 1 corpus biopsy speci-
mens were obtained. One antral biopsy specimen was used for
the RUT, one was used for H. pylori culture, and the rest were
sent for histological examination for H. pylori by hematoxylin-
eosin and Giemsa staining. H. pylori was identified by its
curved-shaped morphology, location on the epithelial cell sur-
face (within the gastric pits or in the overlying mucus layer),
and positive results of Giemsa staining. Additional ulcer-site
biopsy specimens from 4 quadrants were obtained from all
patients with gastric ulcer. Specimens were examined by ex-
perienced pathologists who were blinded to all clinical infor-
mation, including the RUT results. In this study, diagnosis of
H. pylori infection required 2 positive results of the 3 tests
(RUT, histological examination, and 13C-UBT). This approach
has been validated at our health care center before with an
accuracy of 100% [25]. All patients included in this study had
2 positive results for the 3 indirect tests and a positive H.
pylori culture result.
Culture and antibiotic resistance testing. Antral biopsy
specimens were obtained during upper endoscopy and trans-
ported to the laboratory immediately. H. pylori was cultured
from gastric biopsy specimens on selective media (Columbia
agar with 7% horse blood and H. pylori–selective supplement;
Oxoid) under microaerophilic conditions produced by a gas-
generating system (CampyGen; Oxoid) for 3–6 days. H. pylori
was confirmed by Gram staining and by positive urease,
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Table 1. Demographic characteristics of study patients and week 6 Helicobacter pylori eradication
rates.
Variable
Patients with available
metronidazole
susceptibility data
(n p 196)
Patients with available
clarithromycin
susceptibility data
(n p 196)
MtzS isolates
(n p 122)
MtzR isolates
(n p 74)
ClaS isolates
(n p 169)
ClaR isolates
(n p 27)
Age, mean years 50.2 47.5 49.9 44.5
Sex, no. of patients
Male 57 32 81 8
Female 65 42 88 19
Diagnosis
Nonulcer dyspepsia (n p 104) 61 43 87 17
Duodenal ulcer (n p 83) 56 27 74 9
Gastric ulcer (n p 9) 5 4 8 1
H. pylori eradication rate, n/N (%)
ITT analysis 107/122 (87.7)a 50/74 (67.6) 146/169 (86.4)b 11/27 (40.7)
PP analysis 107/120 (89.2)a 50/70 (71.4) 146/165 (88.5)b 11/25 (44.0)
NOTE. ClaR, clarithromycin-resistant; ClaS, clarithromycin-susceptible; ITT, intention-to-treat; MtzR, metronidazole-
resistant; MtzS, metronidazole-susceptible; PP, per protocol.
a , compared with MtzR strains.P ! .01
b , compared with ClaR strains.P ! .001
oxidase, and catalase test results. Metronidazole and clarith-
romycin susceptibility testing was performed using the Etest
(AB Biodisk). Metronidazole resistance was defined as an MIC
of 18 mg/L. Clarithromycin resistance was defined as an MIC
of 12 mg/L. Etest results were validated using the agar dilution
method in our laboratory. Agreement between Etest and agar
dilution results was determined by error-rate bounded analy-
sis to be 95.4% for metronidazole and 100% for clarithro-
mycin [26].
13C-UBT. A 13C-UBT was performed for all patients using
75 mg 13C-urea and analyzed by a mass spectrometer designed
mainly for 13C-UBT analysis. In brief, patient fasted for 4 h
before the test. No test meal was given, and a predose breath
sample was obtained. Seventy-five milligrams of 13C-urea pow-
der dissolved in 50 mL of water was given orally. The second
breath sample was obtained 30 min after the dose. The cutoff
value used was 5%. All patients were kept in a sitting position
during the whole testing period. Samples were analyzed by the
purpose-built isotope ratio mass spectrometer. This protocol
has been validated in our center and has a sensitivity and a
specificity of 96.5% and 97.7%, respectively [27].
Treatment of H. pylori infection and outcome. All patients
received a standard 1-week course of triple-therapy containing
omeprazole (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), and
metronidazole (400 mg b.i.d.). Endoscopy (RUT, histological
examination, and culture) and 13C-UBT were repeated 6 weeks
after completion of drug treatment. Successful eradication was
indicated if the results of RUT, histological examination, cul-
ture, and 13C-UBT were all negative.
Statistical analysis. Statistical tests used included the x2
test, Fisher’s exact test, Student’s t test, and the Mann-Whitney
U test for data with skewed distribution. A P value of .05
was considered statistically significant. All P values were 2-sided.
The intention-to-treat (ITT) analysis included all patients who
had taken 1 tablet of the drugs. In the per-protocol (PP)
analysis, patients with poor drug compliance (!75% intake of
doses of any study drugs) and patients who refused follow-up
were excluded. Multiple logistic regression analysis was per-
formed to determine the factors (age of !40 years, sex, me-
tronidazole resistance, clarithromycin resistance, and diagnosis
of nonulcer dyspepsia) associated with successful eradication
of H. pylori.
RESULTS
Eighty-three patients with duodenal ulcers, 104 patients with
nonulcer dyspepsia, and 9 patients with gastric ulcers who sat-
isfied the inclusion and exclusion criteria were recruited (table
1). There were 89 men and 107 women, with a mean age of
49.2 years (range, 19–78 years). There was no age difference
between men and women (49.0 years vs. 49.4 years, respectively;
). Most (99.5%) of the patients were ethnic Chinese; 1Pp .85
patient was Indian. There was no age difference between the
duodenal ulcer, nonulcer dyspepsia, and gastric ulcer groups,
Metronidazole and Clarithromycin Resistance • CID 2003:37 (1 October) • 885
Figure 1. Prevalence of metronidazole susceptibility (MtzS) and clar-
ithromycin susceptibility (ClaS) among 196 Helicobacter pylori isolates.
ClaR, clarithromycin resistance; MtzR, metronidazole resistance.
but there were significantly more women in the nonulcer dys-
pepsia group (62%) than in the duodenal ulcer group (45%;
).Pp .021
Pretreatment H. pylori culture results. Of the 196 H. pylori
strains isolated, 74 (37.8%) were metronidazole resistant. The
mean age of patients who were infected with metronidazole-
resistant strains was similar to the mean age of those who were
not (47.5 years vs. 50.2 years, respectively; ). There wasPp .21
no statistical difference in the prevalence of metronidazole re-
sistance between men and women from all age groups. The over-
all prevalence of metronidazole resistance was similar between
men (32 [36%] of 89) and women (42 [39%] of 107; ).Pp .64
The prevalence of metronidazole resistance was similar between
patients with nonulcer dyspepsia (43 [41%] of 104) and those
with duodenal ulcers (27 [33%] of 83; ).Pp .43
Of the 196 H. pylori strains isolated, 27 (13.8%) were clar-
ithromycin resistant. The mean age of patients who were in-
fected with clarithromycin-resistant strains was similar to the
mean age of those who were not (44.5 years vs. 49.9 years,
respectively; ). There was no statistical difference in thePp .08
prevalence of clarithromycin resistance between the men and
women of all age groups. The overall prevalence of clarithro-
mycin resistance among women (19 [17.8%] of 107) was not
significantly different from that among men (8 [9.0%] of 89;
). The prevalence of clarithromycin resistance was sim-Pp .08
ilar between patients with nonulcer dyspepsia (9 [11.7%] of
77) and those with duodenal ulcers (17 [15.5%] of 110; Pp
). The prevalence of metronidazole resistance (4 [44.4%] of.60
9) and clarithromycin resistance (1 [11.1%] of 9) among pa-
tients with gastric ulcers was similar to that for patients with
nonulcer dyspepsia and patients with duodenal ulcer. Dual re-
sistance to metronidazole and clarithromycin was found in 17
(8.7%) of the 196 patients (figure 1).
Effect of age. For patients aged 19–49 years, the prevalence
of metronidazole resistance (as determined by Etest) was 42%–
45% (figure 2). The rate decreased to ∼30% for patients aged
50 years (46 [44%] of 105 vs. 28 [31%] of 91 patients;
), but the difference was not statistically significant. InPp .06
contrast, the rate of clarithromycin resistance was 26%–29%
for patients aged 19–39 years and decreased significantly to
6%–13% for patients aged 40 years (14 [28%] of 50 vs. 13
[9%] of 146 patients; ; figure 2).Pp .001
MIC distribution. The distribution of metronidazole MIC
values is* shown in figure 3. Among patients infected with
metronidazole-resistant strains, there was no difference in the
mean MIC value between patients with successful eradication
versus patients for whom eradication failed (159 mg/L vs. 140
mg/L, respectively; )—that is, the MIC value did notPp .53
matter once it became 18 mg/L. Furthermore, among patients
infected with metronidazole-resistant strains, the eradication
rate was similar between patients with high metronidazole re-
sistance values (MIC, 256 mg/L) and patients with low me-
tronidazole resistance values (MIC, !256 mg/L; 67.6% vs. 75%,
respectively; ). The MIC values for clarithromycin arePp .496
shown in figure 4 and had a bimodal distribution pattern.
Factors affecting eradication rates and the development of
posteradication resistance. Six patients refused the week 6
endoscopic examination or were lost to follow-up and were
excluded from PP analysis. No patient was excluded because
of poor drug compliance (i.e., intake of !75% of doses). There
were no hospitalizations or deaths related to treatment. H. pylori
eradication failed in 33 patients. ITT and PP eradication rates
were 80.1% (157 of 196 patients included in the ITT analysis)
and 82.6% (157 of 190 patients included in the PP analysis),
respectively. All patients with eradicated infection had concor-
dant H. pylori test results.
For the 33 patients for whom eradication failed, 20 had
concordant H. pylori test results (i.e., positive results of RUT,
histological examination, culture, and 13C-UBT), 10 had neg-
ative culture results only, and 3 had negative results of RUT
and histological examination only. The H. pylori eradication
rates determined by ITT and PP analyses were significantly
higher among metronidazole-susceptible strains (ITT analysis,
87.7%; PP analysis, 89.2%) than among metronidazole-resis-
tant strains (ITT analysis, 67.6%; PP analysis, 71.4%) (Pp
and , respectively). Similarly, the H. pylori erad-.001 Pp .002
ication rates determined by ITT and PP analyses were higher
among clarithromycin-susceptible strains (ITT analysis, 86.4%;
PP analysis, 88.5%) than among clarithromycin-resistant
strains (ITT analysis, 40.7%; PP analysis, 44%) ( andP ! .001
, respectively). The ITT eradication rate was signifi-P ! .001
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Figure 2. Prevalence of metronidazole and clarithromycin resistance in relation to age
cantly higher in the duodenal ulcer group than in the nonulcer
dyspepsia group (88% vs. 75%; ).Pp .026
Patients for whom H. pylori eradication failed were signifi-
cantly younger than were patients with successful eradication
(43 vs. 50 years old; ). Furthermore, the eradicationPp .011
rate was significantly lower among patients aged !40 years than
among patients aged 40 years (63% vs. 87%; ). OnP ! .001
multiple logistic regression analysis, younger age (!40 years;
OR, 3.25; 95% CI, 1.26–8.38; ), metronidazole resis-Pp .015
tance (OR, 3.04; 95% CI, 1.21–7.61; ), clarithromycinPp .018
resistance (OR, 5.78; 95% CI, 1.98–16.9; ), and thePp .001
diagnosis of nonulcer dyspepsia (OR, 2.79; 95% CI, 1.03–7.60;
) were independent factors for treatment failure.Pp .044
Week 6 H. pylori culture results were available for 24 of the
33 patients for whom eradication of H. pylori failed. The prev-
alences of posttreatment metronidazole resistance, clarithro-
mycin resistance, and dual resistance were 88% (21 of 24 pa-
tients), 88% (21 of 24), and 75% (18 of 24), respectively.
Pretreatment metronidazole resistance was present in 14 (67%)
of 21 patients with posttreatment metronidazole resistance, and
pretreatment clarithromycin resistance was present in 10 (48%)
of 21 patients with posttreatment clarithromycin resistance.
Month 12 H. pylori data (from 13C-UBT) were available for 101
patients in which H. pylori had been eradicated; of these pa-
tients, only 1 (1%) had positive results at month 12. This patient
declined further endoscopic examination.
DISCUSSION
The present study showed that the prevalence of metronidazole-
resistant strains was similar between patients with nonulcer
dyspepsia and those with duodenal ulcers, and the prevalence
was also similar between men and women. The prevalence of
metronidazole-resistant strains was lower among patients aged
50 years old. This was different from our previous report
[12], in which the frequency of metronidazole resistance (as
measured by the disk diffusion method) was lower among per-
sons with duodenal ulcers than among asymptomatic control
subjects. Furthermore, the number of culture-positive cases in
the previous study was only 69, and the culture-positive women
were significantly older than culture-positive men (59.1 vs. 45.8
years; ). These 2 differences were resolved in the pre-Pp .008
sent study, in which the age distribution was similar between
men and women, and the higher number of culture-positive
cases may have theoretically decreased the bias because of a
small sample size. Metronidazole and clarithromycin suscep-
tibility in this study were measured by Etest, which is highly
reliable for testing the antimicrobial susceptibility of H. pylori
and has been validated in our population [26, 28]. Therefore,
we believe that the present report is a better reflection of the
clinical situation in Hong Kong.
A higher prevalence of clarithromycin-resistant strains was
observed in patients aged !40 years. The exact reason is unclear,
but this may be a contributing factor to the lower eradication
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Figure 3. Distribution of MICs of metronidazole for 196 Helicobacter pylori isolates
Figure 4. Distribution of MICs of clarithromycin for 196 Helicobacter pylori isolates
rate observed in patients aged !40 years. A study from France
of 2751 patients who received H. pylori eradication therapy
found that old age, short duration of therapy (i.e., !10 days),
and nonulcer dyspepsia were risk factors for treatment failure
[29]. In a meta-analysis of short (7-day) versus long (14-day)
therapy with a PPI, clarithromycin, and either metronidazole
or amoxicillin for the treatment of H. pylori infection, an im-
provement in cure rates of 7%–9% was observed among re-
cipients of the 14-day regimen. However, the ability of a longer
duration of therapy to overcome clarithromycin resistance has
not been well established [30]. A recent study from Australia
also failed to show a beneficial effect associated with 14 days
of bismuth triple-therapy over 7-day PPI triple-therapy in a
population with a high rate of metronidazole resistance [31].
The ITT H. pylori eradication rate was 20.1% higher among
metronidazole-susceptible strains than among metronidazole-
resistant strains ( ). The observation of a higher erad-Pp .001
ication rate for metronidazole-susceptible strains has been well
reported [16–19]. However, there have been very few reports
on the correlation between the level of metronidazole resistance
and the eradication rate. Me´graud et al. [22] performed large-
scale antimicrobial susceptibility testing of H. pylori recovered
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from patients with duodenal ulcers. MICs of metronidazole of
128 mg/L, 64 mg/L, and 32 mg/L were responsible for a sig-
nificantly higher risk of failure than was an MIC of 16 mg/L.
In contrast, there was no difference in the eradication rate be-
tween patients with high-level metronidazole resistance (MIC,
256 mg/L) and those with low-level metronidazole resistance
(MIC, 18 mg/L and !256 mg/L; 67.6% vs. 75%; ) inPp .496
our study. Jeong et al. [15] suggested that high-level metroni-
dazole resistance is due to sequential inactivation of rdxA and
frxA nitroreductase genes and possibly other unknown genes. A
possible side effect of these multiple mutations is a decrease in
survival fitness of the organism. This may partially explain the
findings of our study.
The ITT eradication rate was 45% lower among clarithro-
mycin-resistant strains and correlated well with previous data.
Furthermore, 52% of patients for whom clarithromycin-
containing eradication therapy failed developed posttreatment
resistance, and our results predict that a poor outcome would
have occurred if clarithromycin had been readministered for
treatment failure [32].
By multiple logistic regression analysis, younger age, metro-
nidazole resistance, clarithromycin resistance, and diagnosis of
nonulcer dyspepsia were significant factors for treatment fail-
ure. As mentioned above, patients of young age had a higher
prevalence of metronidazole and clarithromycin resistance in
our cohort. A recent study from the United States suggested
an association between metronidazole resistance rate and young
age, but older age was significantly associated with clarithro-
mycin resistance [33]. The reason for the opposite trend of
clarithromycin resistance in Chinese persons is uncertain but
may be associated with the genetic heterogeneity of H. pylori
strains or a difference in antibiotic prescription patterns. In-
terestingly, the eradication rate among patients with nonulcer
dyspepsia was 13% lower than the rate among patients with
duodenal ulcers. This finding has been reported previously [34–
37]. The reason was unknown but may be related to differences
in H. pylori strains harbored by these infected individuals. It
has been shown that strains positive for cagA (the cytotoxin-
associated gene) and vacA (vacuolating cytotoxin) were more
commonly found in patients with peptic ulcer disease. Cure
rates seem to be higher for patients with cagA+/vacA s1 (signal
sequence) H. pylori strains, which is consistent with the higher
cure rate observed among patients with ulcers than those with
nonulcer dyspepsia [38]. Because the same treatment regimen
was used, and because almost all subjects were ethnic Chinese,
the explanation is likely to be related to the difference in H.
pylori strains between patients with nonulcer dyspepsia and
those with duodenal ulcers. Analyses of these H. pylori strains
are currently under way.
In conclusion, we have shown that metronidazole resistance,
clarithromycin resistance, younger age, and diagnosis of non-
ulcer dyspepsia significantly affect the success of eradication
therapy in an area with a high rate of metronidazole resistance.
Rates of posttreatment resistance were high, and this resistance
was related to the presence of pretreatment antibiotic resistance.
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